SCHEMBL1241452

SCHEMBL1241452

O=c1ccccn1C(c1cccc(NCCO)n1)C(c1cccnc1)c1cccnc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNE1 P15382 1/20 0.37
KCNA5 P22460 1/20 0.37
KCNQ1 P51787 1/20 0.37
KCND3 Q9UK17 1/20 0.37
MAP4K4 O95819 2/20 0.36
MINK1 Q8N4C8 2/20 0.36
CLK4 Q9HAZ1 2/20 0.36
DYRK3 O43781 1/20 0.36
JAK2 O60674 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKD3 O94806 1/20 0.36
CDK1 P06493 1/20 0.36
PIM1 P11309 1/20 0.36
CDK2 P24941 1/20 0.36
MAPK1 P28482 1/20 0.36
AKT2 P31751 1/20 0.36
FLT4 P35916 1/20 0.36
CDK8 P49336 1/20 0.36
CLK2 P49760 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1242470 0.84 KCNE1 (0.38) KCNE1KCNA5KCNQ1KCND3ITGB3
SCHEMBL1380215 0.80 KCNA5 (0.48) KCNE1KCNA5KCNQ1KCND3MAP4K4
SCHEMBL1242211 0.79 KCNA5 (0.33) KCNE1KCNA5KCNQ1KCND3SMN1; SMN2
SCHEMBL1243091 0.76 KCNA5 (0.40) KCNE1KCNA5KCND3ALDH1A1SMN1; SMN2
SCHEMBL1243310 0.76 KCNA5 (0.40) KCNE1KCNA5KCND3ALDH1A1SMN1; SMN2
SCHEMBL1241967 0.76 KCNA5 (0.40) KCNE1KCNA5KCND3ALDH1A1SMN1; SMN2
SCHEMBL1242156 0.76 CFTR (0.42) KCNA5KDM4EGAASMN1; SMN2MAPT
SCHEMBL3831628 0.73 KCNA5 (0.64) KCNE1KCNA5KCNQ1KCND3MAP4K4
SCHEMBL1242437 0.70 KCNA5 (0.42) KCNE1KCNA5KCNQ1KCND3POLB
SCHEMBL1242623 0.69 KCNA5 (0.44) KCNE1KCNA5KCNQ1KCND3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781635-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2012-06-13 EP disclosed
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090794-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNE1 23/4885KCNA5 11/4885KCNQ1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.